宅男视频

In the photo: Mr Haruo Naito, CEO of Eisai at the 10-year anniversary symposium of Eisai-UCL Collaboration (8 September 2022).

The Eisai-宅男视频 collaboration has been running since December 2012, spearheaded by the UCL Translational Research Office and the Dean of Faculty Brain Sciences. The extension of this long-standing partnership allows both parties to assess deliverables from a decade of working together and to reflect on future priorities and objectives. It also showcases how academia and industry can work together effectively to develop novel therapeutics for neurodegenerative diseases.

Supported through the 拢10M investment, seven drug discovery projects have been initiated so far, tackling a range of pathogenic mechanisms in neurodegeneration, including mitochondrial and lysosomal dysfunction, neuroinflammation, and protein dyshomeostasis.听 The most advanced project from the collaboration, a tau therapeutic is now in Phase 2 clinical trials and has seen a remarkable progression from concept to human translation in 6 years.

The strong foundation and trust established through working together for a decade has led to additional collaborative programs between the two parties. This includes jointly funded PhD programmes to support students and researchers from UCL to foster research into neurodegenerative conditions and advance therapeutic translation.

During the two-year extension, the joint team of senior scientists will continue with two of the existing projects and start to develop further projects exploring drug discovery in the field of neurodegeneration. A team of up to 5 scientists have been recruited to work on these projects across the course of the collaboration.

Dr听Jane Kinghorn, Director of UCL Translational Research Office said: 鈥淭he structure of the collaboration is unique and is distinct from simply awarding an academic laboratory an industry grant. The key factor to the success of this collaboration is the long-term commitment of both partners driven by common objectives and a collaboration model that is flexible enough to embrace the inevitable challenges posed by drug discovery collectively. At the TRO, we are enthusiastic to continue driving sustained engagement of both industry and academia and support the achievements of such partnerships in delivering impact to our patients.鈥�

Dr Teiji Kimura, Senior Group Officer, Academia Industry Alliance Officer, DHBL, Eisai Co Ltd听said, 鈥淭he achievement of the collaboration would not have been possible without the invaluable contribution of UCL scientists and the unique collaboration model we have built based on a continuous exchange of ideas and sharing of expertise and resources. The TRO plays an essential role in ensuring the smooth running of the alliance."

Professor Alan Thompson, Dean of UCL Faculty of Brain Sciences, said: "The great achievement of the project is a result of our unique partnership which brings together UCL's world-class academic research capabilities and Eisai's extensive industry, drug discovery expertise. This extension allows us to get even closer to the goal of working together to develop innovative treatments for patients with neurodegenerative diseases."

听

Read more:

• UCL Eisai strategic alliance tackles Alzheimer's and Parkinson's
• UCL and Eisai celebrate 10 years of a strategic partnership to tackle neurodegenerative diseases
  听

Links:

• UCL Faculty of Brain Sciences
• Queen Square Institute of Neurology听
• Dementia Research Centre听
• 听
• UCL Translational Research Office Business & Innovation Group